Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista de Saúde Pública |
Texto Completo: | https://www.revistas.usp.br/rsp/article/view/193411 |
Resumo: | OBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels. |
id |
USP-23_2cf288fddf1f4c8be24a4c3bfb1f072c |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/193411 |
network_acronym_str |
USP-23 |
network_name_str |
Revista de Saúde Pública |
repository_id_str |
|
spelling |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, BrazilPopulation-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, BrazilCOVID-19, epidemiology Seroepidemiologic StudiesImmunity, HerdSocioeconomic FactorsHealth SurveysCOVID-19, epidemiologySeroepidemiologic StudiesImmunity, HerdSocioeconomic FactorsHealth SurveysOBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels.OBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels.Universidade de São Paulo. Faculdade de Saúde Pública2021-11-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/xmlhttps://www.revistas.usp.br/rsp/article/view/19341110.11606/s1518-8787.2021055004075Revista de Saúde Pública; Vol. 55 (2021); 78Revista de Saúde Pública; Vol. 55 (2021); 78Revista de Saúde Pública; v. 55 (2021); 781518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/rsp/article/view/193411/178260https://www.revistas.usp.br/rsp/article/view/193411/178259Copyright (c) 2021 Aluísio J D Barros, Cesar G Victora, Ana M B Menezes, Bernardo L Horta, Fernando C Barros, Fernando P Hartwig, Gabriel D Victora, Luis Paulo Vidaletti, Mariângela F Silveira, Marilia A Mesenburg, Nadège Jacques, Cláudio J Struchiner, Flávia Roberta Brust, Marinel M Dall’Agnol, Ana Paula Longaray Delamare, Carlos Henrique R François, Maria Letícia R Ikeda, Débora C P Pellegrini, Cézane Priscila Reuter, Shana G da Silva, Odir A Dellagostin, Pedro C Hallalhttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBarros, Aluísio J DVictora, Cesar G Menezes, Ana M BHorta, Bernardo L Barros, Fernando C Hartwig, Fernando PVictora, Gabriel D Vidaletti, Luis PauloSilveira, Mariângela FMesenburg, Marilia AJacques, NadègeStruchiner, Cláudio J Brust, Flávia RobertaDall’Agnol, Marinel MDelamare, Ana Paula LongarayFrançois, Carlos Henrique RIkeda, Maria Letícia RPellegrini, Débora C P Reuter, Cézane PriscilaSilva, Shana G daDellagostin, Odir AHallal, Pedro C2021-12-13T18:57:48Zoai:revistas.usp.br:article/193411Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2021-12-13T18:57:48Revista de Saúde Pública - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil |
title |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil |
spellingShingle |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil Barros, Aluísio J D COVID-19, epidemiology Seroepidemiologic Studies Immunity, Herd Socioeconomic Factors Health Surveys COVID-19, epidemiology Seroepidemiologic Studies Immunity, Herd Socioeconomic Factors Health Surveys |
title_short |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil |
title_full |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil |
title_fullStr |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil |
title_full_unstemmed |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil |
title_sort |
Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil |
author |
Barros, Aluísio J D |
author_facet |
Barros, Aluísio J D Victora, Cesar G Menezes, Ana M B Horta, Bernardo L Barros, Fernando C Hartwig, Fernando P Victora, Gabriel D Vidaletti, Luis Paulo Silveira, Mariângela F Mesenburg, Marilia A Jacques, Nadège Struchiner, Cláudio J Brust, Flávia Roberta Dall’Agnol, Marinel M Delamare, Ana Paula Longaray François, Carlos Henrique R Ikeda, Maria Letícia R Pellegrini, Débora C P Reuter, Cézane Priscila Silva, Shana G da Dellagostin, Odir A Hallal, Pedro C |
author_role |
author |
author2 |
Victora, Cesar G Menezes, Ana M B Horta, Bernardo L Barros, Fernando C Hartwig, Fernando P Victora, Gabriel D Vidaletti, Luis Paulo Silveira, Mariângela F Mesenburg, Marilia A Jacques, Nadège Struchiner, Cláudio J Brust, Flávia Roberta Dall’Agnol, Marinel M Delamare, Ana Paula Longaray François, Carlos Henrique R Ikeda, Maria Letícia R Pellegrini, Débora C P Reuter, Cézane Priscila Silva, Shana G da Dellagostin, Odir A Hallal, Pedro C |
author2_role |
author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Barros, Aluísio J D Victora, Cesar G Menezes, Ana M B Horta, Bernardo L Barros, Fernando C Hartwig, Fernando P Victora, Gabriel D Vidaletti, Luis Paulo Silveira, Mariângela F Mesenburg, Marilia A Jacques, Nadège Struchiner, Cláudio J Brust, Flávia Roberta Dall’Agnol, Marinel M Delamare, Ana Paula Longaray François, Carlos Henrique R Ikeda, Maria Letícia R Pellegrini, Débora C P Reuter, Cézane Priscila Silva, Shana G da Dellagostin, Odir A Hallal, Pedro C |
dc.subject.por.fl_str_mv |
COVID-19, epidemiology Seroepidemiologic Studies Immunity, Herd Socioeconomic Factors Health Surveys COVID-19, epidemiology Seroepidemiologic Studies Immunity, Herd Socioeconomic Factors Health Surveys |
topic |
COVID-19, epidemiology Seroepidemiologic Studies Immunity, Herd Socioeconomic Factors Health Surveys COVID-19, epidemiology Seroepidemiologic Studies Immunity, Herd Socioeconomic Factors Health Surveys |
description |
OBJECTIVE: To describe the evolution of seropositivity in the State of Rio Grande do Sul, Brazil, through 10 consecutive surveys conducted between April 2020 and April 2021. METHODS: Nine cities covering all regions of the State were studied, 500 households in each city. One resident in each household was randomly selected for testing. In survey rounds 1–8 we used the rapid WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China). In rounds 9–10, we used a direct ELISA test that identifies IgG to the viral S protein (S-UFRJ). In terms of social distancing, individuals were asked three questions, from which we generated an exposure score using principal components analysis. RESULTS: Antibody prevalence in early April 2020 was 0.07%, increasing to 10.0% in February 2021, and to 18.2% in April 2021. In round 10, self-reported whites showed the lowest seroprevalence (17.3%), while indigenous individuals presented the highest (44.4%). Seropositivity increased by 40% when comparing the most with the least exposed. CONCLUSIONS: The proportion of the population already infected by SARS-Cov-2 in the state is still far from any perspective of herd immunity and the infection affects population groups in very different levels. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11-22 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/193411 10.11606/s1518-8787.2021055004075 |
url |
https://www.revistas.usp.br/rsp/article/view/193411 |
identifier_str_mv |
10.11606/s1518-8787.2021055004075 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/193411/178260 https://www.revistas.usp.br/rsp/article/view/193411/178259 |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/xml |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
dc.source.none.fl_str_mv |
Revista de Saúde Pública; Vol. 55 (2021); 78 Revista de Saúde Pública; Vol. 55 (2021); 78 Revista de Saúde Pública; v. 55 (2021); 78 1518-8787 0034-8910 reponame:Revista de Saúde Pública instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista de Saúde Pública |
collection |
Revista de Saúde Pública |
repository.name.fl_str_mv |
Revista de Saúde Pública - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
revsp@org.usp.br||revsp1@usp.br |
_version_ |
1800221802455105536 |